Dr. Mohit Saxena has following Publications-. 1st author. Publication High dose Ara-C (Cytosine arabinoside) as a culprit of leukoencephalopathy in a patient of acute myeloid leukemia: A case report Vidarbha Journal of Internal Medicine Published in Vol.19, July 20152. 1st author Publication Experience of Sorafenib as first line treatment in metastatic renal cell carcinoma in a tertiary care center International Journal of hematology-oncology and stem cell research Published in Vol. 12, July 2018 Research/Scientific work - 1. A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-Center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy. (Principal Investigator). 2. A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of Osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA) (Principal Investigator). 3. A multicenter, open-label, single-arm, phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with Trastuzumab and a Taxane (Co-Investigator). 4. ML29662: A multicenter, open-label, single-arm, phase IV study of Trastuzumab Emtansine in Indian patients with HER2 positive unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a Taxane. (Co-Investigator). 5. A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). (Co-Investigator). 6. A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients (KESTREL) (Co-Investigator). 7. A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with advanced Hepatocellular Carcinoma (HIMALAYA). (Co-Investigator). 8. A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with platinum-based Chemoradiation Therapy in Patient with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III) (Co-Investigator). 9. A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer (MonarchE) (Co-Investigator). 10. An open label, single arm, multicenter, safety study of Atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract (Co-Investigator). 11. “A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma or PD-L1 positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)” (Co-Investigator)Others-1. Merit (9th) in 12TH Board of Secondary Education, Rajasthan in year 19982. Topper (General Category) in Rajasthan Pre Medical Test in year 20003. Member of organizing committee in 65th APICON 20104. Training of Good Clinical Practice Workshop in Dec. 20125. Participation in zonal round of Torrent Young Scholar Award (TYSA) programme in Dec. 20146. Participation in “20th National CMI in Hematology” in Jan.-Feb. 20157. Participation in “Innovations in Oncology- Lung cancer edition” in April 20178. Faculty in the “Management of Cancer Thyroid : Paradigms & Challenges” in 20189. Participation in “1st Mid year Uro-Oncology update” in August 201910. Participation in “4th Best of WCLC” in September, 201911. Speaker/Faculty in “Oncology, Laser and Eye” in March 202012. Panelist/Faculty in 2nd Knowledge series for Genitourinary cancers year in review 2020.
